---
title: "Koda Full Year 2025 Earnings: EPS: US$0.007 (vs US$0.054 loss in FY 2024)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254953821.md"
description: "Koda (SGX:BJZ) reported its Full Year 2025 results, achieving a revenue of US$52.7 million, a 16% increase from FY 2024. The company posted a net income of US$547,000, recovering from a US$4.52 million loss in the previous year, with an EPS of US$0.007 compared to a loss of US$0.054 in FY 2024. The profit margin improved to 1.0%. Despite these positive results, Koda has three warning signs in its investment analysis, two of which are potentially serious."
datetime: "2025-08-28T08:35:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254953821.md)
  - [en](https://longbridge.com/en/news/254953821.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254953821.md)
---

# Koda Full Year 2025 Earnings: EPS: US$0.007 (vs US$0.054 loss in FY 2024)

## Koda (SGX:BJZ) Full Year 2025 Results

### Key Financial Results

-   Revenue: US$52.7m (up 16% from FY 2024).
-   Net income: US$547.0k (up from US$4.52m loss in FY 2024).
-   Profit margin: 1.0% (up from net loss in FY 2024). The move to profitability was driven by higher revenue.
-   EPS: US$0.007 (up from US$0.054 loss in FY 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

SGX:BJZ Earnings and Revenue History August 28th 2025

_All figures shown in the chart above are for the trailing 12 month (TTM) period_

Koda's share price is broadly unchanged from a week ago.

### Risk Analysis

Be aware that Koda is showing **3 warning signs in our investment analysis** and 2 of those are potentially serious...

### Related Stocks

- [BJZ.SG](https://longbridge.com/en/quote/BJZ.SG.md)

## Related News & Research

- [Jito, KODA team up on institutional staking in South Korea](https://longbridge.com/en/news/282576108.md)